News

Supernus Pharmaceuticals Reports Positive Phase 2a Study Results

Supernus Pharmaceuticals Reports Positive Phase 2a Study Results

Promising Results from Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a biopharmaceutical firm dedicated to addressing central nervous system (CNS) disorders, has recently unveiled remarkable data from its exploratory open-label Phase 2a clinical study concerning SPN-820 and its effects on adults experiencing major depressive disorder (MDD). This landmark study indicates rapid improvement in depressive symptoms, providing hope for those suffering from this challenging mental health condition.

Overview of the Phase 2a Study

The Phase 2a clinical trial involved a total of 40 participants, with 38 completing the treatment over a 10-day period. The main goal was to assess the safety and effectiveness of SPN-820, which was administered in a dosage of 2400 mg every three days in combination with existing antidepressant treatments. The findings have illustrated significant changes in patients' mental health within a short timeframe.

Key Findings of the Study

Results that emerged from the analysis were both encouraging and statistically significant:

  • Within two hours, patients experienced a clinically relevant improvement of -6.1 on the Hamilton Depression Rating Scale-6 (HAM-D6) and -9.6 by Day 10.
  • On the Montgomery Åsberg Depression Rating Scale (MADRS), scores improved by -16.6 at four hours, reaching -22.9 by Day 10.
  • Remarkably, suicidal ideation saw an 80% decrease, dropping from 12.5% among participants at the outset to just 2.6% by the end of the study.
  • What’s more, SPN-820 demonstrated a high level of tolerability among participants, with very few adverse effects reported, leading to only a 2.5% discontinuation rate.
  • Common side effects included headaches, feelings of nausea, drowsiness, and dizziness, while other minor effects were also noted.

Insights from Leadership

Jack Khattar, President and CEO of Supernus, expressed optimism about SPN-820's potential. He noted, "These Phase 2a data reinforce our belief that SPN-820 may emerge as a new viable treatment option for depression, showing rapid effectiveness without the typical adverse effects. Our goal is to complete patient enrollment for the Phase 2b randomized double-blind placebo-controlled study soon.”

Future Webcast Discussion

Additionally, Supernus will hold a conference call and live webcast to discuss these findings in detail. Stakeholders and the general public can find this important information on the Company’s Investor Relations platform.

About SPN-820

SPN-820 is an innovative oral therapeutic designed to augment mTORC1 activity within the brain, aiming to enhance synaptic functioning. This new treatment avenue is particularly promising due to its ability to induce rapid-onset antidepressant responses, setting it apart from traditional treatments that may take longer to show effectiveness.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals continues to evolve its extensive portfolio, which already includes several approved medications treating conditions such as epilepsy, migraine, and ADHD. The ongoing research aims to expand their offerings into other CNS disorders, reinforcing their commitment to improving mental health and quality of life for patients.

Frequently Asked Questions

What is SPN-820?

SPN-820 is a first-in-class small molecule developed by Supernus Pharmaceuticals aimed at rapidly alleviating symptoms of major depressive disorder.

What were the main findings of the Phase 2a study?

The Phase 2a study showed significant reductions in depressive symptoms and suicidal ideation among participants, indicating it was well-tolerated with few side effects.

Who conducted the Phase 2a study?

The study was conducted by Supernus Pharmaceuticals, which specializes in developing treatments for central nervous system diseases.

When can we expect more results from Supernus?

Further results from the ongoing Phase 2b study of SPN-820 are anticipated in the first half of the upcoming year.

How can interested parties learn more?

For more information, interested individuals can access Supernus Pharmaceuticals' Investor Relations website or participate in the scheduled webcast.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 16

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 310

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 37

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 348

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 513

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading

Top 5 Most Recently Viewed Articles

Motorsport Games Achieves Significant Growth in Q3 Results

Updated Category News Views 182

Motorsport Games Shows Promising Financial Trends Motorsport Games Inc. (NASDAQ: MSGM) recently shared its financial outcomes for the third quarter, reflecting remarkable growth. The company, a key player in the racing game industry, recorded significant advancements, particularly highlighted by their flagship title, Le Mans Ultimate. For Q3 2025, Motorsport Games...

Continue Reading
AI Giants Converge in Singapore for SuperAI 2026

Updated Category News Views 52

SuperAI Singapore 2026: A Global Gathering Singapore's Marina Bay Sands is buzzing, folks. With 10,000 people crammed into Asia's largest AI event, SuperAI Singapore 2026 is offering up a melting pot of tech brains from 150 countries. It's sold out like your favorite band’s farewell tour—things kicking off with a big bang. A Melting Pot of Innovation You’ve got...

Continue Reading
Investors' Sentiment Towards Terreno Realty Corp Revealed

Updated Category News Views 128

Understanding Investor Sentiment for Terreno Realty Corp Terreno Realty's short interest has notably surged, reflecting a growing sentiment among investors. Currently, 11.02% increase in short interest reveals that now approximately 6.22 million shares are sold short, making it 10.78% of the float. Observing the trading volume suggests that it would take traders roughly...

Continue Reading
Gilead Sciences Targets Growth Amid Oncology Challenges and Opportunities

Updated Category News Views 208

Gilead Sciences faced significant challenges back in 2024 as its oncology ambitions faltered, all while the company leaned heavily on its HIV stronghold. The stock stumbled, reflecting broader market jitters about its future growth potential. You see, Gilead had been riding high on Biktarvy, a blockbuster that held nearly 49% of the U.S. HIV treatment market. Analysts...

Continue Reading
Captify Launches Innovative Election War Room Insights 2024

Updated Category News Views 124

Captify Launches the Election War Room for the 2024 Elections Captify, a leader in real-time audience analytics powered by Search Intelligence, has introduced the Captify Election War Room—a weekly data report that spotlights what people are searching for during the 2024 U.S. election cycle. As the race intensifies, brands and campaign teams want a clearer view of how...

Continue Reading